|
1) Adams HP, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke. A Guideline From the American Heart Association/American Stroke Association Stroke Counsil. Clinical Cardiology Council, Cardiovascular Radiology and Inter-vention Council, and the Atherosclerotic Periph-eral Vascular Disease and Quqlity of Care Out-comes in Research Interdiscriplinary Working Groups. Stroke. 2007; 38: 1655-711
|
|
|
|
2) 脳卒中合同ガイドライン委員会. 脳卒中治療ガイドライン2009. 東京: 協和企画; 2009
|
|
|
|
|
|
3) Lee Y-S, Bae H-J, Kang D-W, et al. Cilostzol in acute ischemic stroke treatment (CAIST trial): a randomized double-blind non-inferiority trial. Cerebrovasc Dis. 2011; 32: 65-71
|
|
|
|
|
|
4) Ridker PM, Cook NP, Lee I-M, et al. A random-ized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005; 352: 1293-304
|
|
|
|
|
|
5) Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of athero-sclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008; 300: 2134-41
|
|
|
|
|
|
6) Belch J, MacCuish A, Cambell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomized placebo controlled trial of aspirin and anti-oxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008; 337: a1840
|
|
|
|
|
|
7) Goldstein LB, Bushnell CD, Adams RJ, et al. Guideline for the primary prevention of stroke. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011; 42: 517-84
|
|
|
|
|
|
8) Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-51
|
|
|
|
|
|
9) Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883-91
|
|
|
|
|
|
10) Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-92
|
|
|
|
|
|
11) Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidenced-based Clinical Practice Guidelines (8th edition). Chest. 2008; 133 Suppl 6: 546S-92S
|
|
|
|
|
|
12) Hart RG, Benavents O, McBride R, et al. Anti-thrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999; 131: 492-501
|
|
|
|
|
|
13) The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrelplus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomizede controlled trial. Lancet. 2006; 367: 1903-12
|
|
|
|
|
|
14) The ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrilla-tion. N Engl J Med. 2009; 360: 2066-78
|
|
|
|
|
|
15) Japan Atrial Fibrillation and Stroke Trial (JAST) Group. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation. Japan Atrial Fibrillation Stroke Trial. Stroke. 2006; 37: 447-51
|
|
|
|
|
|
16) Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack. A guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2011; 42: 227-76
|
|
|
|
|
|
17) Antithrombotic Trialistʼ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-anlysis of individual participant data from randomized trials. Lancet. 2009; 373: 1849-60
|
|
|
|
|
|
18) Sacco RL, Diener H-C, Yusuf S, et al. Aspirin and extended-release dipydamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008; 359: 1238-51
|
|
|
|
|
|
19) 内山真一郎. 日本人脳梗塞患者におけるクロピドグレルの適正用量の検討. 新薬と臨床. 2011; 60: 1124-30
|
|
|
|
|
20) Markus H, Droste DW, Larrue V, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection. The clopidogrel and aspirin for reduction of emboli in symptomatic carotid stenosis (CARESS) trial. Circulation. 2005; 111: 2233-40
|
|
|
|
|
|
21) Wong KSL, Chen C, Fu J, et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolization in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomized, open-label, blinded-endopoint trial. Lancet Neurol. 2010; 9: 489-97
|
|
|
|
|
|
22) Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind randomized non-inferiority trial. Lancet Neurol. 2010; 10: 959-68
|
|
|
|
|
|
23) Kamal AK, Naqvi I, Husain MR, et al. Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin (Review). The Cochrane Library. 2011, Issue 1
|
|
|
|
|
|
24) Huang Y, Cheng Y, Wu J, et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomized, double-blind, pilot study. Lancet Neurol. 2008; 7: 494-9
|
|
|
|
|
|
25) Yamagami H, Sakai N, Matsumaru Y, et al. Periprocedual cilostazol treatment and restenosis after carotid artery stenting: The retrospective study of in-stent restenosis after carotid artery stenting (ReSISteT-CAS). J Stroke Cerebrovasc Dis. 2010 sep 18 [Epub ahead of print]
|
|
|
|
|
|
26) Katakami N, Kim Y-S, Kawamori R, et al. The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus. Principal results of diabetic atherosclerosis prevention by cilostazol (DAPC) study: a randomized trial. Circulation. 2010; 121: 2584-91
|
|
|
|
|
|
27) Ahn CM, Hong SJ, Park JH, et al. Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. Heart Vessels. 2011; 26: 502-10
|
|
|
|
|
|
28) Kwon SU, Hong KS, Kang DW, et al. Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial athero-sclerosis stenosis. Stroke. 2011; 42: 2883-90
|
|
|
|
|
|
29) Bousser M-G, Amarenco P, Chamorro A, et al. Terutroban versus aspirin in patients with cerebral ischaemic events: a randomized, bouble-blind, parallel-group trial. Lancet. 2011; 377: 2013-22
|
|
|
|
|
|
30) Toyoda K, Yasaka M, Iwade K, et al. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease. A prospective, multicenter, observational study. Stroke. 2008; 39: 1740-5
|
|
|
|
|
|
31) Toyoda K, Yasaka M, Uchiyama S, et al. Blood pressure levels and bleeding events during antithrombotic therapy. The bleeding with anti-thrombotic therapy (BAD) study. Stroke. 2010; 41: 1440-4
|
|
|
|
|
|
32) Krasopoulos G, Brister S, Beattie WS, et al. Aspirin “resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008; 336: 195-8
|
|
|
|
|
|
33) 宮田茂樹, 長束一行, 嘉田晃子, 他. A multicenter prospective cohort study on the profile and genetic factors of aspirin resistance-ProGEAR study. 日本脳卒中学会・日本血栓止血学会ジョイントシンポジウム. 2011年7月31日, 京都
|
|
|
|
|
|
34) Fukuoka T, Furuya D, Takeda H, et al. Evaluation of clopidogrel resistance inischemic stroke pa-tients. Intren Med. 2011; 50: 31-5
|
|
|
|
|
|
35) Maruyama H, Takeda H, Dembo T, et al. Clopidogrel resistance and the effect of combi-nation cilostazol in patients with ischemic stroke or carotis stenting using the VerifyNow P2Y12 assay. Intern Med. 2011; 50: 695-8
|
|
|
|
|
36) Vlachojannis GJ, Dimitropoulos G, Alexopoulos D, et al. Clopidogrel resistance: current aspects and future directions. Hellenic J Cardiol. 2011; 52: 236-45
|
|
|
|
|
|
37) Collet J-P, Hulot J-S, Anzaha G, et al. High doses of clopidogrel to overcome genetic resistance. The randomization crossover CLOVIS-2(Clopidogrel and Response Variability Investigation Study 2). J Am Coll Cariol Intv. 2011; 4: 392-402
|
|
|
|
|